Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Chronic Lymphocytic Leukemia Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

15 recruiting trials for Chronic Lymphocytic Leukemia. Eligibility criteria explained in plain English.

TrialFinderData lists 15 Chronic Lymphocytic Leukemia clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 43% (3 studies); the largest phase groups are Phase 2: 3, Phase 1 / Phase 2: 2, Phase 3: 1, Phase 1: 1.

Research is led by University Hospital, Angers (1), UNC Lineberger Comprehensive Cancer Center (1), Thomas Jefferson University (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Biospecimen Collection (procedure, 3 trials), followed by Cyclophosphamide, Questionnaire Administration.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
15
Total Trials
15
Recruiting Now
1
Phase 3 Trials
10
Sponsors

Track Chronic Lymphocytic Leukemia trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06971848

Evaluation of Skin Tests in Biotherapy Allergies

Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory...

Sponsor: University Hospital, AngersEnrolling: 701 location
RECRUITINGNCT06860880

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

This health services study will assess a multidisciplinary intervention program directed at fatigue mitigation among patients diagnosed with indolent lymphomas. Specifically, 30...

Sponsor: UNC Lineberger Comprehensive Cancer CenterEnrolling: 401 location
RECRUITINGPhase 2NCT05031897

Two Step Haplo With Radiation Conditioning

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell...

Sponsor: Thomas Jefferson UniversityEnrolling: 631 location
RECRUITINGPhase 3NCT04269902

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia...

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk...

Sponsor: National Cancer Institute (NCI)Enrolling: 24720 locations
RECRUITINGPhase 1 / Phase 2NCT05959694

A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic...

This is a phase Ib/II clinical trial to evaluate the safety and efficacy of TQB3909 tablets in patients with recurrent or refractory CLL/SLL.

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Enrolling: 10720 locations
RECRUITINGNCT06792994

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients...

This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.

Sponsor: German CLL Study GroupEnrolling: 20002 locations
RECRUITINGPhase 1 / Phase 2NCT05006716

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety...

Sponsor: BeOne MedicinesEnrolling: 64520 locations
RECRUITINGPhase 2NCT04679012

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and...

Sponsor: Weill Medical College of Cornell UniversityEnrolling: 204 locations
RECRUITINGPhase 1NCT06037018

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies

This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and...

Sponsor: CytoCares IncEnrolling: 441 location
RECRUITINGNCT05334069

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and...

Sponsor: Alliance for Clinical Trials in OncologyEnrolling: 200020 locations
RECRUITINGNCT03375619

Long-term Follow-up Study of Patients Receiving CAR-T Cells

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert...

Sponsor: Medical College of WisconsinEnrolling: 5001 location
RECRUITINGNCT06784167

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as...

Sponsor: OHSU Knight Cancer InstituteEnrolling: 451 location
RECRUITINGPhase 2NCT03314974

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or,...

Sponsor: Masonic Cancer Center, University of MinnesotaEnrolling: 3001 location
RECRUITINGNCT05643235

Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable...

Sponsor: Northwell HealthEnrolling: 501 location
RECRUITINGNCT06475469

Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive...

Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in western countries. CLL is most often discovered incidentally when a blood test carried out for another...

Sponsor: CHU de ReimsEnrolling: 751 location

Frequently Asked Questions

There are currently 15 clinical trials for Chronic Lymphocytic Leukemia, with 15 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Chronic Lymphocytic Leukemia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Chronic Lymphocytic Leukemia, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.